

Washington University School of Medicine

Digital Commons@Becker

---

2020-Current year OA Pubs

Open Access Publications

---

5-1-2023

## Functional screening of lysosomal storage disorder genes identifies modifiers of alpha-synuclein neurotoxicity

Meigen Yu

Hui Ye

Ruth B. De-Paula

Carl Grant Mangleburg

Timothy Wu

*See next page for additional authors*

Follow this and additional works at: [https://digitalcommons.wustl.edu/oa\\_4](https://digitalcommons.wustl.edu/oa_4)

 Part of the [Medicine and Health Sciences Commons](#)

Please let us know how this document benefits you.

---

---

**Authors**

Meigen Yu, Hui Ye, Ruth B. De-Paula, Carl Grant Mangleburg, Timothy Wu, Tom V. Lee, Yarong Li, Duc Duong, Bridget Phillips, Carlos Cruchaga, Genevera I. Allen, Nicholas T. Seyfried, Ismael Al-Ramahi, Juan Botas, and Joshua M. Shulman


## RESEARCH ARTICLE

# Functional screening of lysosomal storage disorder genes identifies modifiers of alpha-synuclein neurotoxicity

Meigen Yu<sup>1</sup>, Hui Ye<sup>2</sup>, Ruth B. De-Paula<sup>3</sup>, Carl Grant Mangleburg<sup>4,5</sup>, Timothy Wu<sup>4,5</sup>, Tom V. Lee<sup>2</sup>, Yarong Li<sup>2</sup>, Duc Duong<sup>6</sup>, Bridget Phillips<sup>7,8</sup>, Carlos Cruchaga<sup>7,8</sup>, Genevera I. Allen<sup>9,10</sup>, Nicholas T. Seyfried<sup>6</sup>, Ismael Al-Ramahi<sup>4,10,11</sup>, Juan Botas<sup>3,4,10,11</sup>, Joshua M. Shulman<sup>1,2,4,10,11</sup>\*

**1** Department of Neuroscience, Baylor College of Medicine, Houston, Texas, United States of America, **2** Department of Neurology, Baylor College of Medicine, Houston, Texas, United States of America, **3** Quantitative and Computational Biology Program, Baylor College of Medicine, Houston, Texas, United States of America, **4** Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, United States of America, **5** Medical Scientist Training Program, Baylor College of Medicine, Houston, Texas, United States of America, **6** Departments of Biochemistry and Neurology, Emory University School of Medicine, Atlanta, Georgia, United States of America, **7** Department of Psychiatry, Washington University, St. Louis, Missouri, United States of America, **8** NeuroGenomics and Informatics, Washington University, St. Louis, Missouri, United States of America, **9** Departments of Electrical and Computer Engineering, Computer Science, and Statistics, Rice University, Houston, Texas, United States of America, **10** Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, Texas, United States of America, **11** Center for Alzheimer's and Neurodegenerative Diseases, Baylor College of Medicine, Houston, Texas, United States of America

\* [Joshua.Shulman@bcm.edu](mailto:Joshua.Shulman@bcm.edu)



## OPEN ACCESS

**Citation:** Yu M, Ye H, De-Paula RB, Mangleburg CG, Wu T, Lee TV, et al. (2023) Functional screening of lysosomal storage disorder genes identifies modifiers of alpha-synuclein neurotoxicity. *PLoS Genet* 19(5): e1010760. <https://doi.org/10.1371/journal.pgen.1010760>

**Editor:** Bingwei Lu, Stanford University School of Medicine, UNITED STATES

**Received:** July 25, 2022

**Accepted:** April 25, 2023

**Published:** May 18, 2023

**Copyright:** © 2023 Yu et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** *Drosophila* proteomics data are included with [supporting information \(S1 and S2 Datasets\)](#). Human proteomics were obtained from the Parkinson's Progression Markers Initiative (PPMI) database ([www.ppmi-info.org/access-data-specimens/download-data](http://www.ppmi-info.org/access-data-specimens/download-data)). In order to ensure regulatory compliance for human subjects research and the informed consent process, PPMI data are available to qualified investigators following submission of a data use agreement and short online application.

## Abstract

Heterozygous variants in the *glucocerebrosidase (GBA)* gene are common and potent risk factors for Parkinson's disease (PD). *GBA* also causes the autosomal recessive lysosomal storage disorder (LSD), Gaucher disease, and emerging evidence from human genetics implicates many other LSD genes in PD susceptibility. We have systemically tested 86 conserved fly homologs of 37 human LSD genes for requirements in the aging adult *Drosophila* brain and for potential genetic interactions with neurodegeneration caused by  $\alpha$ -synuclein ( $\alpha$ Syn), which forms Lewy body pathology in PD. Our screen identifies 15 genetic enhancers of  $\alpha$ Syn-induced progressive locomotor dysfunction, including knockdown of fly homologs of *GBA* and other LSD genes with independent support as PD susceptibility factors from human genetics (*SCARB2*, *SMPD1*, *CTSD*, *GNPTAB*, *SLC17A5*). For several genes, results from multiple alleles suggest dose-sensitivity and context-dependent pleiotropy in the presence or absence of  $\alpha$ Syn. Homologs of two genes causing cholesterol storage disorders, *Npc1a / NPC1* and *Lip4 / LIPA*, were independently confirmed as loss-of-function enhancers of  $\alpha$ Syn-induced retinal degeneration. The enzymes encoded by several modifier genes are upregulated in  $\alpha$ Syn transgenic flies, based on unbiased proteomics, revealing a possible, albeit ineffective, compensatory response. Overall, our results reinforce the important role of lysosomal genes in brain health and PD pathogenesis, and implicate several metabolic pathways, including cholesterol homeostasis, in  $\alpha$ Syn-mediated neurotoxicity.

All numerical data contributing to graphical and statistical analysis is included in the [S3 Dataset](#).

**Funding:** JMS, JB, and NTS were supported by grants from the National Institutes of Health (U01AG061357, R01AG057339). JMS was additionally supported by NIH (R21AG068961), Huffington Foundation, the Burroughs Wellcome Foundation (Career Award for Medical Scientists), the Effie Marie Cain Chair in Alzheimer's Research, a gift from Terry and Bob Lindsay, and the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital. MY was supported by a grant from the National Institutes of Health (F31NS115364). HY received support from the Parkinson's Foundation (PF-PRF-830012) and Alzheimer's Association (AARF-21-848017). The Pathology and Histology Core at Baylor College of Medicine is supported by NIH grant P30CA125123. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** The authors have declared that no competing interests exist.

## Author summary

Parkinson's disease (PD) is characterized clinically by progressive decline in both motor and non-motor brain functions, and pathologically by the aggregation of alpha-synuclein protein along with neuron loss. Partial loss-of-function in the *glucocerebrosidase* (*GBA*) gene causes a 5-fold increased risk of PD. By contrast, nearly complete loss of *GBA* causes a distinct disorder called Gaucher's disease, and other metabolic genes that cause lysosomal storage disorders (LSDs) have been similarly implicated in PD risk. Using a fruit fly model, we have tested 86 conserved homologs of human LSD genes for interactions with alpha-synuclein-induced neurotoxicity. Our screen identified 15 enhancers of progressive locomotor dysfunction, including knockdown of fly homologs of *GBA*, other LSD genes with support from human genetics, as well as new candidate PD genes, such as *LIPA* and *NPCI*, which are involved in cholesterol metabolism. Our results suggest that partial loss of many LSD genes may enhance alpha-synuclein-mediated PD risk and pathogenesis, whereas more complete loss impairs nervous system function independent of alpha-synuclein. We also discover that alpha-synuclein may trigger increases of selected LSD proteins. Overall, this work reinforces the important role of lysosomal metabolism in brain health and PD pathogenesis.

## Introduction

Parkinson's disease (PD) is a common and incurable neurodegenerative disorder with strong evidence for genetic etiology [1]. Heterozygous carriers for variants in the *glucocerebrosidase* (*GBA*) gene have an approximately 5-fold increased risk of PD, and *GBA* variants also modify PD clinical manifestations, causing more rapid progression and susceptibility for dementia [1,2]. Whereas partial loss-of-function is associated with PD, complete or near-complete loss of *GBA* causes Gaucher disease, a recessive lysosomal storage disorder (LSD) [3,4]. *GBA* encodes the lysosomal enzyme glucocerebrosidase (GCase), which catalyzes the breakdown of glucosylceramide, a substrate that accumulates along with other, more complex sphingolipids in Gaucher disease and possibly PD [5].

There are more than 50 different LSDs, which are similarly characterized by defects in lysosomal biogenesis and/or function, and lead to heterogeneous clinical manifestations, including neurodegeneration in many cases [6]. Emerging evidence from human genetics suggests that other LSD genes, beyond *GBA*, may also influence PD susceptibility. For example, heterozygous carriers of loss-of-function variants in *SMPD1*, which cause Niemann Pick Disease type A/B, have been shown to increase PD risk [7]. Moreover, in independent studies, an aggregate burden of rare, damaging variants in LSD genes was associated with PD, and this relation was robust to exclusion of *GBA* [8,9]. Although the rarity of variants limits statistical power to definitively establish the responsible genes, suggestive evidence implicates possible roles for *CTSD*, *SLC17A5*, and *ASAHI* [8]. Lastly, based on genome-wide association study meta-analysis, common variants implicate several other LSD genes at PD risk loci, including *SCARB2*, *GRN*, *GUSB*, *GALC*, and *NAGLU* [10].

While the precise mechanism by which *GBA* variants affect PD risk remains unknown, substantial evidence points to interactions with  $\alpha$ -synuclein protein ( $\alpha$ Syn), which aggregates to form Lewy body pathology.  $\alpha$ Syn disrupts endolysosomal trafficking, including transport of GCase and other lysosomal enzymes, leading to reduced enzymatic activity and metabolic perturbations [11,12]. Reciprocally, loss of GCase may promote Lewy body pathology due to increased  $\alpha$ Syn protein and aggregation [13], resulting from impaired lysosomal autophagy

[14] and sphingolipid substrate accumulation [12,15,16]. In this study, we leverage a versatile *Drosophila* model to systematically test the hypothesis that other LSD genes may similarly interact with  $\alpha$ -synuclein-mediated neurotoxic mechanisms. Our results highlight requirements for many LSD genes in the maintenance of central nervous system (CNS) structure and function, and further reinforce links with PD pathogenesis.

## Results


### Associations of LSD genes with PD risk

Previously, we and others have discovered evidence for an aggregate burden of rare genetic variants among LSD genes in association with PD risk [8,9]. Although several LSD genes have also been implicated at susceptibility loci from PD genome-wide association studies [10], to our knowledge, a systematic analysis for common variant associations across all LSD genes has not been performed. Leveraging publicly available summary statistics from 56,306 PD cases and 1.4 million control subjects [10], we used the multi-marker analysis of genomic annotation (MAGMA) tool [17] to examine LSD genes for enrichment of variants associated with PD. MAGMA computes an overall gene-set test statistic considering all variants falling within gene intervals, including adjustments for gene size and regional linkage disequilibrium. The full LSD gene set was significantly enriched for variants associated with PD risk ( $n = 51$  loci,  $p = 0.0011$ ) (S1 Table); the X-linked LSD genes (*GLA*, *IDS*, and *LAMP2*) were excluded from the available genome-wide association dataset. In order to identify possible drivers for the gene set association, we examined MAGMA output considering each of the LSD genes independently. These results identify *GBA* and 9 other LSD genes with aggregate evidence for common variant associations ( $p < 0.05$ ): *IDUA*, *SCARB2*, *CLN8*, *GNPTAB*, *ARSA*, *GALC*, *CLN5*, *NAGLU*, and *CTSD*. We also performed a sensitivity analysis showing that the LSD gene set association remains significant after excluding either *GBA* ( $n = 50$  loci,  $p = 0.014$ ) or the top 3 genes (*GBA* plus *SCARB2* and *IDUA*) ( $n = 47$  loci,  $p = 0.03$ ), which are similarly localized to regions with genome-wide significant associations in the dataset. These results reinforce the genetic connection between causes of LSDs and PD, revealing an important role for common variant associations.

### Screen for LSD gene modifiers of $\alpha$ -synuclein-mediated neurotoxicity

Due to the rarity of pathogenic variants, human genetic studies are underpowered to comprehensively resolve all of the LSD genes contributing to PD risk and pathogenesis [8]. As a complementary approach, and to systematically test the hypothesis that LSD genes may broadly interact with  $\alpha$ Syn-mediated neurotoxicity, we implemented a cross-species strategy. Pan-neuronal expression of the human *SNCA* gene in the fruit fly, *Drosophila melanogaster*, causes Lewy body-like  $\alpha$ Syn aggregates, lysosomal stress, dopaminergic and other neuronal loss, and progressive locomotor impairment [18,19]. We therefore performed a genetic modifier screen examining for interactions between homologs of human LSD genes and  $\alpha$ Syn-induced neurotoxicity, using locomotor behavior as a readout for CNS function (Fig 1). Out of 53 human LSD genes [8], 39 (74%) are conserved in flies (S2 Table). Overall, our screen considered 86 homologs (many genes had multiple conserved homologs), and we obtained 259 distinct strains for genetic manipulation, including RNA interference (RNAi) and other available alleles (mean of  $\sim 3$  independent experimental manipulations per gene; S3 Table). We employed an automated locomotor behavioral assay based on the *Drosophila* negative geotactic response, which is highly amenable for high-throughput genetic screening [20,21].

Compared to controls (*elav-GAL4* / +), pan-neuronal expression of human  $\alpha$ Syn (*elav* >  $\alpha$ Syn / +) causes progressive locomotor impairment (Fig 2A). RNAi transgenes targeting the




**Fig 1. Study flowchart.** Out of 53 human LSD genes, 86 are conserved in *Drosophila* and have available lines for genetic screening. 259 genetic fly strains, including RNAi and insertional or classical alleles, were tested for interaction with the locomotor phenotype induced by pan-neuronal  $\alpha$ -synuclein ( $\alpha$ Syn) expression. Screening revealed 15 fly genes for which gene loss significantly enhances the  $\alpha$ Syn phenotype. Based on further tests of all modifying strains in the absence of  $\alpha$ Syn, genes were further classified as synergistic or additive. Synergistic genes were defined as having *at least one* modifying allele in which there was no significant evidence of locomotor impairment in the absence of  $\alpha$ Syn.

<https://doi.org/10.1371/journal.pgen.1010760.g001>

fly homologs of human LSD genes were coexpressed throughout the nervous system with  $\alpha$ Syn using the same *elav-GAL4* driver, and climbing speed of adult flies was evaluated longitudinally between 1 and 3 weeks of age. All transgenes were tested in heterozygosity. *Drosophila* RNAi lines are designed for optimal specificity [22,23]. To further minimize the possibility of off-target effects, we only considered genes as modifiers when supported by consistent evidence from at least two independent RNAi strains or other alleles. Overall, our screen identified 15 fly genetic modifiers of  $\alpha$ Syn, homologous to 14 human LSD genes (two different paralogs of *SCARB2* were identified as modifiers) (Fig 3). In all cases, genetic manipulations predicted to reduce the function of LSD gene homologs (RNAi knockdown or other loss-of-function alleles) enhanced the *elav*> $\alpha$ Syn locomotor phenotype (Figs 2B–2E and S1).

Since LSDs are frequently associated with neurologic manifestations, we reasoned that knockdown of *Drosophila* homologs would likely cause CNS dysfunction in many cases, independent of  $\alpha$ Syn expression. Therefore, we also tested all modifying lines from our screen (35 RNAi and other alleles) to examine the consequences for locomotor behavior in the absence of



**Fig 2. Lysosomal storage disorder (LSD) gene homologs show dose-sensitivity and context-dependent pleiotropy in *Drosophila*.** (A) Pan-neuronal expression of human  $\alpha$ -synuclein (*elav* >  $\alpha$ Syn) induces progressive locomotor impairment. (B) Pan-neuronal knockdown (KD) of LSD gene homologs with RNA-interference (RNAi) enhances the  $\alpha$ Syn locomotor phenotype. RNAi transgenes were tested in heterozygosity. In the absence of  $\alpha$ Syn, KD (*elav* > RNAi) causes no (*LIPA/Lip4*: v31021), moderate (*GLB1/Ect3*: 3132R1), or severe (*NPC1/Npc1a*: v105405) toxicity. (C) Additional synergistic gene modifiers enhance  $\alpha$ Syn following KD, but do not cause significant locomotor impairment in the absence of  $\alpha$ Syn (*SCARB2/Smp1*: v42496; *GBA/Gba1b*: v21336; and *SMPD1/CG15533*: v42520). (D and E) Heterozygous loss-of-function alleles of *Npc1a* (D) and *Csp* (E) dominantly enhance  $\alpha$ Syn. Climbing speed was assessed longitudinally including at least 11 aged time points over 30 days ( $n > 6$  replicates of 15 animals each). Statistical comparisons based on one-way ANOVA considering three nested models (genotype, genotype + time, and genotype\*time) and reporting results for the most complex model meeting significance. \*\*\*,  $p < 5 \times 10^{-5}$ . See also S1 Fig for comprehensive results from validation tests of all other genes/alleles, and S5 Table for detailed statistical output.

<https://doi.org/10.1371/journal.pgen.1010760.g002>



	Human Gene	Fly Gene	Interaction
Glycosaminoglycan	<i>GLB1</i>	<i>Ect3</i>	A
	<i>IDS</i>	<i>Ids</i>	S
	<i>IDUA</i> *	<i>Idua</i>	A
	<i>MAN2B1</i>	<i>LManII</i>	A
	<i>MANBA</i>	$\beta$ - <i>Man</i>	A
Sphingolipid	<i>GBA</i> *	<i>Gba1b</i>	S
	<i>SCARB2</i> *	<i>Dsb</i>	A
		<i>Snmp1</i>	S
	<i>SMPD1</i> *	<i>CG15533</i>	S
Chol.	<i>LIPA</i>	<i>Lip4</i>	S
	<i>NPC1</i>	<i>Npc1a</i>	S
Other	<i>CTSD</i> *	<i>CG10104</i>	A
	<i>DNAJC5</i>	<i>Csp</i>	A
	<i>GNPTAB</i> *	<i>Gnptab</i>	A
	<i>SLC17A5</i> *	<i>MFS3</i>	A

**Fig 3. Lysosomal storage disorder (LSD) gene modifiers of  $\alpha$ -synuclein ( $\alpha$ Syn).** Human LSD genes and *Drosophila* homologs identified as modifiers are indicated. Human genes with additional supportive evidence as PD risk loci from human genetics are noted with an asterisk (\*). Based on further tests to establish  $\alpha$ Syn-dependent or independent activity, genes were further classified as synergistic (S) or additive (A). Synergistic genes were defined as having at least one modifying allele in which there was no significant evidence of locomotor impairment in the absence of  $\alpha$ Syn. Additive genes were characterized by alleles that consistently produced locomotor phenotypes in the absence of  $\alpha$ Syn. All modifier genes had at least one allele establishing  $\alpha$ Syn-independent functional requirements in the fly nervous system.

<https://doi.org/10.1371/journal.pgen.1010760.g003>

$\alpha$ Syn (e.g., *elav*>*RNAi* / + versus *elav*-*GAL4* / +). These experiments revealed a range of phenotypic severity (Figs 2B and S1), with some RNAi lines showing little or no locomotor phenotype (e.g., *LIP4* / *Lip4*) and others with mild (e.g., *GLB1* / *Ect3*) or more substantial, age-dependent impairments (e.g., *NPC1* / *Npc1a*). Based on these results, we classified the 15 genes as either “additive” or “synergistic” modifiers of  $\alpha$ Syn (Fig 3). Synergistic modifiers had at least one modifying allele in which there was no significant evidence of locomotor impairment in the absence of  $\alpha$ Syn (Fig 2C). Overall, 6 of 15 genes, including *Gba1b*, the *Drosophila* homolog of *GBA*, showed evidence of synergistic interactions with  $\alpha$ Syn mediated neurotoxicity. The




remaining “additive” genetic modifiers were characterized by alleles that consistently produced locomotor phenotypes in the absence of  $\alpha$ Syn. Notably, all LSD modifier genes had at least one allele tested revealing  $\alpha$ Syn-independent functional requirements in the aging nervous system.

In humans, *GBA* reveals dose-sensitive and pleiotropic effects on disease traits, causing Gaucher disease and also increasing susceptibility for PD. In *Drosophila*, our screen results also suggest that many LSD gene homologs may have similar dose-dependent relationships (S1 Fig). For 3 loci, including *GBA* (*Gba1b*), *IDS* (*Ids*), and *LIPA* (*Lip4*), knockdown with multiple, independent RNAi transgenes targeting each of these genes showed consistent enhancement of  $\alpha$ Syn-induced locomotor impairment, but differential requirements in the absence of  $\alpha$ Syn. For selected genes, classical mutant alleles were also available and permitted evaluation of potential heterozygous interactions. Strikingly, heterozygous loss-of-function alleles for both *Npc1a* and *Csp*, homologous to human *NPC1* and *DNAJC5*, respectively, dominantly enhanced  $\alpha$ Syn, but caused little to no phenotype when examined on their own (Figs 2D, 2E and S1). By contrast, RNAi-knockdown of both genes induced a marked locomotor phenotype independent of  $\alpha$ Syn (Figs 2B and S1). Overall, our results are potentially consistent with a model in which partial loss of function for multiple LSD genes may enhance  $\alpha$ Syn neuropathology, as with *GBA*-PD, but that more complete loss of gene function may compromise CNS function, as in neuronopathic Gaucher disease and many other LSDs. For several genes of interest, we confirmed that both RNAi and heterozygous loss-of-function alleles caused decreased gene expression; however, we were not able to establish a predictable relationship between degree of knockdown and severity of locomotor phenotype, at least based solely on mRNA levels (S2 Fig; see also Discussion).

### Cholesterol metabolism and $\alpha$ -synuclein mediated neurotoxicity

LSDs are commonly classified based on the metabolic pathways disrupted and characteristic type of substrate accumulation. For example, *GBA*, *SCARB2*, and *SMPD1*, which are collectively implicated in PD risk, are also jointly involved in sphingolipid metabolism; fly homologs of all 3 genes (*Gba1b*, *Dsb*, and *CG15533*, respectively) were identified in our screen as synergistic, loss-of-function enhancers of  $\alpha$ Syn. Among our results, *Npc1a* and *Lip4* are both fly homologs of genes causing the human cholesterol storage disorders, Niemann Pick Disease type C (*NPC1*) and cholesterol ester storage disease (*LIPA*). Both *Npc1a* and *Lip4* were notable for robust, synergistic enhancement following gene knockdown or in the presence of heterozygous mutant alleles, consistent with dose-sensitive interactions with  $\alpha$ Syn-mediated neuronal injury (Fig 2B and 2D). Notably, pan-neuronal overexpression of either gene using available lines did not suppress but rather mildly enhanced the  $\alpha$ Syn locomotor phenotype, consistent with a one-way interaction (S3 Fig; see also Discussion). Whereas *Lip4* has not been well-characterized in flies, loss of *Npc1a* causes the accumulation of cholesterol, defective synaptic transmission, and ultimately, neurodegeneration, similar to human Nieman Pick type C [24]. We confirmed significant, albeit modest, elevations of total cholesterol levels in fly heads following genetic manipulations of either *Npc1a* or *Lip4* (S4 Fig).

The lysosome has been implicated as an important regulator of  $\alpha$ Syn proteostasis and toxicity. In order to begin to address potential mechanisms by which loss-of-function in cholesterol storage disorder genes might enhance  $\alpha$ Syn-mediated neuronal injury, we therefore examined two well-established markers of lysosomal function [25]: the autophagy mediator, p62, and Cathepsin L, which is cleaved to generate a mature enzyme. However, following genetic manipulations of *Npc1a* or *Lip4*, we did not detect any changes in either of these markers to suggest a global lysosomal dysfunction (S5 and S6 Figs). Moreover, using a sensitive ELISA



**Fig 4. Cholesterol storage disorder gene homologs enhance  $\alpha$ -synuclein ( $\alpha$ Syn) induced retinal degeneration.** (A) Expression of  $\alpha$ Syn in the adult retina ( $Rh1 > \alpha$ Syn) causes progressive neurodegeneration compared with controls ( $Rh1$ -GAL4/+). Knockdown (KD) of *Lip4* ( $Rh1 > v31021$  / +) or heterozygosity for a *Npc1a* loss-of-function allele enhances  $\alpha$ Syn-mediated tissue destruction. Tangential retinal sections from 15 day-old animals were stained with hematoxylin and eosin. (B) Quantification based on extent of vacuolar changes (vacuole area / total area) from at least  $n = 6$  animals per genotype. Statistical comparisons were made using unpaired t-tests, followed by Dunnett's post-hoc test. Error bars represent the standard error of the mean. \*\*\*,  $p < 0.001$ ; ns, not significant. Scale bar =  $20\mu\text{m}$ . See also S8 Fig for results using additional RNAi and alleles.


<https://doi.org/10.1371/journal.pgen.1010760.g004>

assay, we confirmed that levels of total  $\alpha$ Syn protein were largely stable following manipulations of *Npc1a* or *Lip4* as well as all other LSD gene modifiers identified in our screen (S7 Fig).

In order to confirm the interactions between  $\alpha$ Syn and *Npc1a* and *Lip4*, we used an independent retinal neurodegeneration assay. We previously established that expression of  $\alpha$ Syn in adult photoreceptors using the *Rh1*-GAL4 driver ( $Rh1 > \alpha$ Syn) causes age-dependent structural degeneration [25], with mild vacuolar changes manifested at 15 days, based on hematoxylin and eosin staining of tangential sections through the retina (Figs 4 and S8). RNAi-mediated *Lip4* knockdown or a heterozygous *Npc1a* loss-of-function allele significantly increased  $\alpha$ Syn-induced retinal degeneration, but similar changes were not seen in corresponding controls. These results are consistent with the findings from our screen and further implicate lysosomal regulators of cholesterol metabolism in  $\alpha$ Syn-mediated neurotoxicity.

### $\alpha$ -synuclein pathology causes altered expression of LSD enzymes

To further explore underlying mechanisms, we generated unbiased mass-spectrometry proteomics from  $\alpha$ Syn (*elav > \alphaSyn* / +) and control (*elav*-GAL4 / +) animals, using the same



**Fig 5. Differential expression of lysosomal storage disorder (LSD) protein homologs in flies.** Comparisons of protein abundance (normalized) from fly heads are shown for *elav*> $\alpha$ Syn (Gray) or control (White, *elav-GAL4* / +), based on Tandem Mass Tag proteomics. t-tests were performed for comparisons of mean abundance considering  $n = 8$  replicate samples for each genotype. Error bars represent the standard error of the mean. \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ . All proteins shown were also significantly differentially expressed based on analyses in DESeq2 (Wald test) and following adjustment using the Benjamini-Hochberg procedure ( $p_{\text{adj}} < 0.05$ ). See also S4 Table and S9 Fig for replication analysis using an independent longitudinal *Drosophila* proteomics dataset.

<https://doi.org/10.1371/journal.pgen.1010760.g005>

genotypes as in our locomotor screen and initially choosing a timepoint (10-days) that is predicted to be early in the overall pathologic progression. From these data, 48 *Drosophila* homologs of human LSD proteins were detected. Strikingly, 22 fly proteins (homologous to 16 human proteins encoded by LSD genes) were significantly differentially expressed following pan-neuronal expression of  $\alpha$ Syn in the adult brain (Fig 5 and S4 Table), including 15 up- and 7 down-regulated proteins. Importantly, many proteins overlapped with genetic modifiers identified in our screen. In an independent longitudinal proteomics dataset we replicated  $\alpha$ Syn-induced increases among 6 of these proteins (S9 Fig), including Npc1a and several proteins homologous to human LSD gene products causing mucopolysaccharidoses: GLB1/Ect3, MAN2B1/LManII, and MANBA/Beta-Man. Collectively, these enzymes participate in the breakdown of glycosaminoglycans (Fig 3). To further establish translational relevance, we next interrogated human cerebrospinal fluid proteomics from the Parkinson's Progression Markers Initiative (PPMI) study. Of the 6 LSD gene modifiers with increased expression levels in  $\alpha$ Syn flies, only MANBA was detected in the PPMI dataset. Interestingly, MANBA protein levels were significantly elevated in prodromal PD and subsequently reduced in clinically manifest PD (S9 Fig). Prodromal PD is defined as the presence of early disease biomarkers, but preceding clinical manifestations required for the diagnosis of PD (see Methods). Since gene loss-of-function in *Drosophila* enhances the  $\alpha$ Syn locomotor phenotype, the increased protein expression of MANBA and other modifying genes may be consistent with a potential compensatory response to lysosomal stress (see below).

## Discussion

Mounting evidence supports an important connection between the genetic mechanisms of LSDs and PD. Using a cross-species, functional screening strategy, we discover 14 conserved

human LSD genes with homologs that robustly enhance  $\alpha$ Syn-mediated neurotoxicity when their activity is reduced in *Drosophila* models. The majority of these genes also show evidence for  $\alpha$ Syn-independent requirements, and in several cases our data is suggestive of dose-sensitivity and context-dependent pleiotropy similar to *GBA* in PD and Gaucher disease. Two of the genes identified by our screen, *GBA* and *SMPDI*, are established PD risk genes [2,7,26], and our results confirm and extend data from other animal and cellular models (discussed below). In other cases, the evidence from human genetics may be more modest, but our discovery of genetic interactions with  $\alpha$ Syn mechanisms increases the possibility that these genes may be *bona fide* PD risk factors. For example, in our prior analysis of exome sequencing data, *CTSD* and *SLC17A5* showed suggestive associations with PD risk [8]; however, the rarity of variants and available sample sizes have limited statistical power to confirm such loci. Our results also provide experimental support for LSD genes, such as *SCARB2* and *GNPTAB*, which are candidates at susceptibility loci from PD GWAS [10]. Indeed, GWAS rarely identify responsible genes definitively, but instead highlight regions that usually contain many viable candidates. As a group, we and others previously showed that genes causing LSDs harbor an aggregate burden of damaging rare variants among PD cases [8]. Here, using available GWAS data, we also demonstrate similar significant enrichment for more common variants associated with PD risk. Overall, the LSD genes prioritized by our functional screening strategy are outstanding candidates for further investigation as PD risk factors, including using both human genetics and experimental approaches.

Animal and cellular model experimental studies highlight several plausible mechanisms for how LSD genes might interact with and enhance  $\alpha$ Syn-mediated neurotoxicity. First, LSD gene loss-of-function may impair turnover and thereby increase accumulation of toxic  $\alpha$ Syn species. For example, *CTSD* encodes a lysosomal cathepsin, which can directly degrade  $\alpha$ Syn [27,28]. More indirectly, reduced LSD gene activity may promote the accumulation of undigested substrates that secondarily accelerate  $\alpha$ Syn misfolding or aggregation. In a variety of systems, glucosylceramide and its derivatives (e.g., glucosylsphingosine) have been shown to interact with  $\alpha$ Syn in this manner [15,16]. Notably, based on a sensitive ELISA assay we did not detect any consistent evidence of elevated total  $\alpha$ Syn protein levels following LSD gene knockdown, but it may be important to instead directly examine toxic, aggregated forms. Alternatively, it is possible that LSD gene dysfunction may also promote lysosomal stress and reduced autophagic flux [29,30]. However, we did not find support for this based on markers of lysosomal function, at least from studies conducted at a single, early timepoint.

In prior work, experimental manipulations of *GBA*, *SMPDI*, and *SCARB2*—which similarly cause sphingolipid storage disorders—have been demonstrated to induce accumulation and toxicity of  $\alpha$ Syn [12,26,31]. Beyond sphingolipid/ceramide metabolism, our screen also identifies many fly homologs of genes causing human mucopolysaccharidoses (e.g., *GLB1*, *IDS*, *IDUA*, *MAN2B1*, *MANBA*). These disorders are characterized by accumulation of glycosaminoglycans, which are long chains of repeating, negatively charged disaccharide units that can be linked to protein cores to form proteoglycans. Though perhaps less well studied than sphingolipids, recent studies suggest that glycosaminoglycan metabolites have the potential to similarly influence  $\alpha$ Syn aggregation [32]. In addition, proteoglycans are abundant at the cell surface and are a major constituent of the extracellular matrix, having recently been implicated in the propagation and/or internalization of pathologic  $\alpha$ Syn species [33]. Interestingly, in one recent human genetic analysis, the genes causing mucopolysaccharidoses comprised a major driver for the rare variant burden association with PD risk among LSD genes [9]. Our screen also identifies homologs of two causes of cholesterol storage disorders, *LIPA* and *NPCI*. Cholesterol content may also be an important modulator of interactions between  $\alpha$ Syn and the neuronal membrane, with consequences for synaptic transmission and PD pathologic

progression [34,35]. In fact, conflicting epidemiologic studies have linked hypercholesterolemia to either increased [36] or decreased [37–39] PD risk, whereas other studies have found no such association [40]. To date, there has been no definitive genetic evidence for association of *NPC1* with PD risk [41,42]; however, subclinical metabolic perturbations [43,44] or parkinsonian signs [45,46] have been reported in heterozygous carriers of loss-of-function variants. Lastly, it is possible that disparate molecular pathways interact and feedback on one another within the lysosomal milieu. For example, loss of *NPC1* in Niemann Pick Disease type C leads to accumulation not only of cholesterol, but also secondary perturbations in sphingolipids and glycosaminoglycans [47]. Thus, it is conceivable that subtle perturbations affecting one enzymatic transformation might trigger a cascading metabolic failure that amplifies  $\alpha$ Syn mediated neurotoxicity.

Ultimately, a successful mechanistic model must account for both the pleiotropic potential of LSD genes and their exquisite, dose-dependent interactions with  $\alpha$ Syn-mediated PD mechanisms. Strikingly, whereas only a modest reduction of GCase enzymatic activity confers increased PD risk (e.g., ~75% residual function in carriers of the *GBA*<sup>E356K</sup> allele) [48], Gaucher disease requires near complete loss of function (e.g., less than 15% residual GCase activity) [49]. Based on our screen, nearly all fly homologs of human LSD genes were capable of causing locomotor dysfunction independent of  $\alpha$ Syn. This result is consistent with an obligate role for most LSD genes in the maintenance of CNS structure and function. By contrast, more modest loss-of-function in many LSD genes strongly enhanced the  $\alpha$ Syn locomotor phenotype but caused little or no CNS dysfunction independent of  $\alpha$ Syn. This was best exemplified by fly homologs of *NPC1* and *DNAJC5* (*Npc1a* and *Csp*, respectively) which both showed dominant, heterozygous enhancement of  $\alpha$ Syn neurotoxicity, supporting dose-sensitive interactions. For many other genes, including the *Drosophila* *GBA* homolog, *Gba1b*, we also identified additional RNAi strains that support a synergistic interaction model. Prior studies using human  $\alpha$ Syn transgenic flies have differed on potential synergistic interactions following *Gba1b* manipulation, but these studies have relied on either different alleles and tissue-specific drivers or distinct phenotypic assays [50,51]. Dose-sensitive interactions may arise from positive feedback between aging,  $\alpha$ Syn toxicity, and progressive lysosomal dysfunction. Data from multiple experimental models highlight how  $\alpha$ Syn can disrupt endosomal trafficking pathways, including delivery of GCase and other hydrolases to the lysosome [11,12], and thus may potentiate the impact of partial genetic loss-of-function in LSD genes. These pathologic interactions may be further amplified by aging, which among myriad cellular changes, is accompanied by reduced lysosomal proteostasis (autophagy) [52]. The impact of  $\alpha$ Syn on the lysosome is suggested by our *Drosophila* proteomic profiles, revealing perturbations in the expression of numerous LSD proteins. In particular, the up-regulation detected for 6 modifier genes is consistent with a possible compensatory, albeit ineffective, cellular response, since genetic manipulation in the opposite direction (RNAi knockdown) worsened  $\alpha$ Syn-induced locomotor impairment. Indeed, many lysosomal enzymes are transcriptionally coregulated, and prior studies support a well-conserved response pathway that can be activated in the context of lysosomal stress [53,54]. Notably, overexpression of either *Npc1a* or *Lip4* did not suppress the  $\alpha$ Syn locomotor phenotype. Therefore, whereas knockdown of a given LSD gene in isolation appears sufficient to exacerbate neurodegeneration, targeted overexpression of a single enzyme may be ineffective to ameliorate a more widely distributed lysosomal defect.

The strengths of this study include the cross-species strategy, systematic consideration of multiple alleles for all LSD gene targets, longitudinal data collection, and an analytical framework that accounts for the potential impact of aging. The high-throughput locomotor screening assay is sensitive to early consequences of CNS dysfunction that precede cell death and subsequent structural degenerative changes. For *Npc1a* and *Lip4*, we additionally employed an



independent assay for  $\alpha$ Syn-induced retinal degeneration. One important potential limitation is that all genetic manipulations with RNAi were targeted exclusively to neurons. Many LSD genes, including *GBA*, are also expressed in glia, where they may also have important roles in the maintenance of CNS structure/function [55,56]. While we also tested classical mutant alleles, which are predicted to affect gene function globally, these reagents were only available for a subset of LSD gene homologs. The broad expression pattern for many LSD genes further complicates quantification of RNAi knockdown strength using neuron-specific drivers or comparison with heterozygous loss-of-function alleles. In the future it may also be important to directly assess neuronal cell death following interactions between LSD genes and  $\alpha$ Syn toxicity, including cell-type specific degeneration of dopaminergic and other neurons. In addition, genes with negative results should be interpreted cautiously, since our interaction tests were potentially limited by the availability of RNAi reagents, which sometimes produce only a weak knockdown. Lastly, a minority of LSD genes are non-conserved in the *Drosophila* genome and were therefore not examined, including some with evidence for association with PD risk from human genetics (e.g., *ASAH1*, *GUSB*). Nevertheless, our results confirm and extend the strong genetic link between LSDs and PD and highlight many promising genes and metabolic pathways for further study in PD risk, pathogenesis, and therapy.

## Materials and methods

### LSD gene set enrichment analysis from PD GWAS

PD GWAS summary statistics [10] were analyzed using MAGMA v1.10 [17]. Gene location and European reference files for the GRCh37 genome build were downloaded from MAGMA webpage (<https://ctg.cncr.nl/software/magma>), and the BEDTools v2.26.0 [57] *intersect* function was used to interrogate SNPs from the PD GWAS summary statistics. MAGMA annotation, gene analysis and gene-set analysis steps were performed using default parameters. The list of LSD genes [8] (S1 Table) was used under the *—set-annot* parameter for the gene-set analysis, and selected genes were excluded for the sensitivity analysis. The X-linked LSD genes, *GLA*, *IDS*, and *LAMP2*, were excluded from GWAS, so summary statistics were not available for aggregate variants tests.

### Fly stocks and husbandry

Human  $\alpha$ -synuclein transgenic lines with codon optimization for *Drosophila* were previously described [19]. For locomotor screening, a recombinant second chromosome line harboring 2 *UAS- $\alpha$ -synuclein* insertions was used, as in prior studies [21]. For retinal histology, a third chromosome insertion was employed, also from previous work [25]. The *GAL4-UAS* system [58] was used for ectopic expression of both  $\alpha$ Syn and RNA-interference (RNAi) transgenes. For pan-neuronal expression, we used *elav<sup>c155</sup>-GAL4* [59], which is available from the Bloomington *Drosophila* Stock Center (BDSC; Bloomington, IN, USA). For expression in retinal photoreceptors, we used *Rh1-GAL4* (second chromosome insertion) [25,60]. For the locomotor screen of conserved LSD genes, virgin females obtained from RNAi or other allelic strains were crossed to male *elav<sup>c155</sup>-GAL4 / Y; UAS-SNCA / Cyo,GAL80*. To evaluate  $\alpha$ Syn-independent effects, RNAi or other genetic strains, potential modifier strains were crossed with *elav<sup>c155</sup>-GAL4 / Y* or *w<sup>1118</sup> / Y* males. Only female progeny carry both the *elav-GAL4* driver and the *UAS-SNCA* and/or the *UAS-RNAi* transgenes; therefore, female progeny were used for all experiments (e.g., *elav-GAL4 / +; UAS-SNCA / UAS-RNAi* or *elav-GAL4 / +; UAS-SNCA / allele*). All modifier gene manipulations (RNAi or alleles) were tested in heterozygosity. Crosses and progeny were established and maintained at 25°C. For secondary modifier tests using the  $\alpha$ Syn retinal degeneration assay, all crosses were established at 18°C, and progeny

were shifted to 25°C within 24 hours of eclosion and aged 15 days, following published protocols [25]. RNAi transgenic strains (*UAS-RNAi*) were obtained from the Vienna Drosophila Resource Center (VDRC; Vienna, Austria) [22], BDSC for the Harvard Transgenic RNAi Project [23], and the National Institute of Genetics Fly Stock Center (NIG; Japan). All RNAi lines used for this study are detailed in [S3 Table](#). As a control, we used the VDRC *w<sup>1118</sup>* genetic background strain (line 60000) and *UAS-RNAi-scramble* (*v2691*; VDRC gDNA plasmid *dna451*). Additional alleles for fly homologs of LSD genes, including transposon insertions, other classical mutation alleles, and overexpression transgenic lines, were obtained from BDSC or requested from other laboratories, including *crq<sup>KO</sup>* [61], *dsb<sup>KO</sup>* [62], *UAS-Lip4* [63], *UAS-Npc1a* [64], *Gba1b<sup>KO</sup>* [65], and *Gba1a,b<sup>KO</sup>* [65].

## Genetic screen

The *Drosophila* Integrated Ortholog Prediction Tool (DIOPT) [66] was used to identify all conserved fly homologs of human LSD genes. We required consensus from at least 3 independent bioinformatic algorithms for inclusion of a fly gene homolog (DIOPT score of 3 or greater). Where multiple paralogs met our criteria, we attempted to carry forward all such candidates. In the exceptional cases where more than 5 gene paralogs were identified as potential homologs for a given human gene, a more stringent DIOPT score cut-off was used ([S1 Table](#)). The screen was conducted in two stages. First, 174 RNAi strains from VDRC were obtained to knock down 86 unique homologs of human LSD genes (reagents were not available for 6 conserved genes). Locomotor behavior (see below) was assayed in female adult flies at up to 5 time points between 8 and 18 days post-eclosion. Based on the results, we subsequently obtained an additional 85 lines for further screening, including independent RNAi strains (from BDSC and NIG) and other available alleles. Lastly, for validation of screen results, all modifier genes supported by evidence from multiple independent allelic strains were re-evaluated in both the presence and absence of  $\alpha$ Syn, and locomotor behavior was assayed at 11 or more time points over 30 days of aging.

## Robot-assisted locomotor assay

The negative geotaxis climbing assay was performed using a custom robotic system (SRI International, available in the Automated Behavioral Core at the Duncan Neurological Research Institute), as previously described [20]. Negative geotaxis is elicited by “tapping” vials of flies to knock them to the bottom of custom vials. After three taps, video cameras recorded and tracked the movement of animals at a rate of 30 frames per second for 7.5 seconds. For each genotype, 6–8 replicates of 15 female animals were tested in parallel (biological replicates), and each trial was repeated five times (technical replicates). Replicates were randomly assigned to positions throughout a 96-vial plate and were blinded to users throughout the duration of experiments. Quantification was based on the average climbing speed of flies included in each biological replicate. Speed of individual flies was computationally deconvoluted from video recordings. For configuration and running of the robotic assay and video acquisition, we used the following software packages: Adept desktop, Video Savant, MatLab with Image Processing Toolkit and Statistics Toolkit, RSLogix (Rockwell Automation), and Ultraware (Rockwell Automation). Additional custom software was developed for assay control (SRI graphical user interface for controlling the machine) and analysis [FastPhenoTrack (Vision Processing Software), TrackingServer (Data Management Software), ScoringServer (Behavior Scoring Software), and Trackviewer (Visual Tracking Viewing Software)].



## Adult retina histology

Fly heads from 15-day-old female animals were fixed in 8% glutaraldehyde and embedded in paraffin. Tangential retinal sections (3  $\mu\text{m}$ ) were cut using a Leica Microtome (RM2245) and stained with hematoxylin and eosin. Retinas from at least three animals were examined and quantified for each experimental genotype. Enhancement of  $\alpha\text{Syn}$ -induced retinal degeneration was quantified based on the severity of retinal vacuolar changes seen in stained histologic sections. We examined representative photographs taken with a 40X objective from well-oriented, intact tangential sections at a depth in which the retina achieves maximal diameter. Using ImageJ software [67], we recorded the area occupied by all vacuoles with a diameter greater than 4 $\mu\text{m}$  and divided by the total retinal area to compute a percentage.

## RT-PCR

RNAi knockdown was examined for selected genes of interest, including those (1) related to cholesterol metabolism (*Npc1a*, *Lip4*); (2) synergistic enhancers with evidence from heterozygous loss-of-function alleles (*Npc1a*, *Csp*); and (3) genes with locomotor phenotypes consistent with possible dose-dependence responses to RNAi manipulations (*Gba1b*, *Dsb*, *Beta-Man*). 30 heads per replicate from 10-day-old female flies were homogenized in 1 mL TRIzol Reagent (Invitrogen # 15596026) and RNA was extracted using standard chloroform:phenol methods [68]. Reverse transcription was performed using SuperScript IV VILO Master Mix (Invitrogen # 11756050) using 2  $\mu\text{g}$  RNA per reaction, according to the vendor protocol. cDNA solution was diluted 1:40 to obtain working concentration. Quantitative real-time PCR amplification were performed on 1  $\mu\text{L}$  diluted cDNA in a 10  $\mu\text{L}$  mixture containing SsoAdvanced Universal SYBR Green Supermix (BioRad # 1725271) and specific primers for each gene (see below) on the QuantStudio 5 Real-Time PCR System (Applied Biosystems #A34322). Amplification parameters were as follows: 2 minutes at 50°C, 10 min at 95°C, followed by 40 cycles of 15 sec at 95°C and 1 min at 60°C, with temperature adjustment rates of 1.6°C / second. Relative mRNA expression level was calculated by the threshold cycle (Ct) value of each PCR product and normalized to the average values of *GADPH* and *RPL32* housekeeping genes by using the comparative  $2^{-\Delta\Delta\text{Ct}}$  method [69]. The following primer pairs were used:

RPL32 Forward: ATCGGTTACGGATCGAACAA  
 RPL32 Reverse: GACAATCTCCTTGCCTTCT  
 GAPDH Forward: TAAATTCGACTCGACTCACGGT  
 GAPDH Reverse: CTCCACCACATACTCGGCTC  
 $\beta$ -Man Forward: GCGTTTTCCCATTTGGCAACT  
 $\beta$ -Man Reverse: ACGTCGAACTGAAAGAAATTGGA  
 Csp Forward: TGCGGCTGATAAGTTCAAGGA  
 Csp Reverse: TTCTCCTCGCCAAACTGCTC  
 Dsb Forward: AAAAACC AAAATTGCAAGCAAGAADsb  
 Reverse: CAAGCCCATAATTCAAGTGTTCG  
 Gba1b Forward: CACTGCTTGGCTTTCTTACTACA  
 Gba1b Reverse: GCAGACACACACGCTTCCA  
 Lip4 Forward: CCTCAATTCCACGGGCGTAA  
 Lip4 Reverse: TCAGCTTGAGGACCAACGAT  
 Npc1a Forward: GCTGAAGAAACGCTGTGGATT  
 Npc1a Reverse: GCACCAAGTTCTCCATGCAG

## Western blotting

Adult fly heads were homogenized in 2X Laemmli Sample Buffer (Bio-Rad) with 5%  $\beta$ -mercaptoethanol (Calbiochem) using a pestle (Argos Technologies). The lysates were heated at 95°C for 5 min, followed by centrifugation at  $21,130 \times g$  at 4°C for 15 min before SDS-PAGE analysis. Samples were loaded into 4–12% Bis-Tris gels (Invitrogen), separated by SDS-PAGE. Gels were transferred to PVDF membrane (Millipore), and blocked in Intercept (TBS) Blocking Buffer (LI-COR). We used the following primary antibodies and dilutions: mouse anti-tubulin (DM1A, Sigma Aldrich, RRID:AB\_477583), 11000; Mouse anti-CTSL (clone 193702, MAB22591, R and D Systems, RRID:AB\_2087830), 1:2000; Rabbit anti-p62/Ref(2)p [70] 1:2000. IRDye secondary antibodies (LI-COR) were used in 1X TBST (Tris-buffered saline + 0.1% Tween-20) at 1:5000.

## Enzyme-linked immunosorbent assay (ELISA)

Homogenates were prepared from five 10-day-old female flies heads per replicate in 200  $\mu$ L Denaturing Cell Extraction Buffer (Invitrogen # FNN0091) treated with 1 mM PMSF and protease inhibitor cocktail (Sigma-Aldrich Cat. No. P-2714) using a pestle. Samples were lysed for 30 minutes on ice and spun down at 13,000 rpm for 15 minutes at 4°C, per manufacturer instruction. To detect  $\alpha$ -synuclein protein levels, the alpha Synuclein Human ELISA Kit (Invitrogen # KHB0061) was used according to manufacturer instruction. Briefly, homogenates were diluted 1:25 in ELISA Kit diluent buffer. 50  $\mu$ L diluted homogenate and 50  $\mu$ L Human Synuclein Detection Antibody were applied to each well of the provided antibody-coated microplate and incubated at room temperature for 3 hours. Plate was washed using provided 1X ELISA Wash Buffer, then incubated in 100  $\mu$ L per well Anti-Rabbit IgG HRP for 30 minutes at room temperature. Plate was again washed and incubated in 100  $\mu$ L Stabilized Chromogen per well for 30 minutes at room temperature in the dark. 100  $\mu$ L Stop Solution was added to each well and signal intensity was measured at 450 nm on a FLUOstar OPTIMA plate reader (BMG LABTECH). Each ELISA was performed with 2 technical replicates per biological replicate, as recommended in the ELISA Technical Guide provided by Thermo Fisher Scientific. Standard curves were included for each plate using the provided purified  $\alpha$ -synuclein standards.

## Cholesterol quantification

The Amplex Red Cholesterol Assay Kit (Invitrogen # A12216) was used for sterol detection in fly head homogenates. 5–10 fly heads per replicate from 10-day-old female flies were homogenized in 40  $\mu$ L / head 1X Reaction Buffer from kit using a pestle. Homogenates were vortexed and incubated at 37°C for 10 minutes before spinning down at max rpm for 10 minutes at room temperature. Supernatant was gently mixed before aliquoting, to ensure incorporation of oily lipid layer. In a black polystyrene 96-well plate, 50  $\mu$ L homogenate per well was combined with the assay kit working solution containing Amplex Red Reagent, HRP, and cholesterol oxidase in 1X Reaction Buffer, per manufacturer instructions. Plate was incubated protected from light for 60 minutes at 37°C. FLUOstar OPTIMA plate reader (BMG LABTECH) was used to measure fluorescence at excitation range of 530–560 nm and emission detection at 590 nm. 2 technical replicates were included for each biological replicate. Standard curves were included for each plate using the provided purified cholesterol standards.

## Proteomic analysis of LSD genes

For *Drosophila* proteomics, tandem mass tag mass-spectrometry proteomics was performed for  $\alpha$ Syn transgenic and control flies, using the identical genotypes as the locomotor screen

(*elav>aSyn* and *elav-GAL4 / +*) and following previously published protocols [71]. Homogenates were prepared from adult fly heads aged to 10 days, including 8 biological replicate samples per model consisting of approximately 50 heads each. The full dataset includes quantitation of 6,610 unique proteins and is included as supplemental data (S6 Table and S1 Dataset). Proteins containing missing values were excluded and protein intensity values mapping to the same flybase ID were summed. For this study, our analyses were restricted to 48 *Drosophila* proteins (S4 Table); a more comprehensive, proteome-wide analysis will be reported elsewhere. Differential protein expression was calculated with DESeq2 v1.34.0, as in prior work [72,73] using genotype as a linear regression covariate and using the *lfcShrink* function. The DESeq2 *counts* function was implemented in order to plot normalized abundance. For replication, we leveraged an independent proteomics dataset from *elav>aSyn* and *elav-GAL4 / +* flies, including  $n = 5$  replicate samples and 6 aging timepoints between 2 and 21 days (60 samples total). The full dataset includes 6,128 detected proteins and is included as supplemental data (S7 Table and S2 Dataset).

For proteomic analyses from human CSF, we leveraged samples and data from the Parkinson's Progression Markers Initiative (PPMI; [www.ppmi-info.org](http://www.ppmi-info.org)). PPMI is a longitudinal observational study with comprehensive clinical and imaging data and biological samples. Blood, saliva, or DNA samples were used for genetic mutation testing of LRRK2 (G2019S and R1441G), GBA (N370S) and SNCA mutations. Proteomic data was generated on 1,075 samples using the aptamer-based SomaScan5K platform. A total of 4,783 analytes remain after QC: outliers were removed by 1.5 IQR threshold, aptamer and individual call rate <65%, and aptamer and individual call rate <85%. 917 samples were present with PPMI phenotypes including 185 control subjects without PD, 545 PD cases, and 187 subjects with prodromal PD. Prodromal PD is defined as the presence of REM sleep behavior disorder and/or genetic risk factors along with hyposmia and (in most cases) neuroimaging evidence of a dopamine transporter deficit, but these subjects lack clinical manifestations allowing the diagnosis of PD. MANBA had one analyte in the Soma5K dataset. 736 total PPMI samples had both diagnosis and protein data. Violin plots were generated in R via the *ggplot2* and *ggsignif* packages.

## Statistical analysis

MAGMA analysis was performed using default parameters. An F-test was performed to compute gene p-values. For gene set analyses, p-values are converted to Z-values, and a competitive analysis is performed, returning an overall T-test p-value. Data from our robotic *Drosophila* locomotor assay was processed by first calculating mean and standard deviation values for climbing speed across the replicates of each genotype tested using the *mean* and *sd* functions in R [74]. Each experimental genotype was compared against all control genotypes tested on the robotic assay at the same time for all downstream statistical analyses. Within-tray analyses were conducted to minimize differences between groups of flies (potential batch effects). We employed longitudinal mixed effects models in our analyses to better represent the age-dependent changes which we hypothesized were modified by differences in genotype. These models were implemented using the *lme4* package in R [75]. We used a random intercept term to model the mean climbing speed of each genotype and smoothing splines (cubic B-splines) to capture non-linear trends over time [76]. We tested the differences between all possible pairs of genotypes within each tray by testing the interactions between genotypes and their B-splines using one-way ANOVA (*aov* function in R) with three nested statistical models of increasing complexity: (i) genotype, (ii) genotype + time, and (iii) genotype\*time. The genotype-only model examined mean shifts in climbing speed between genotypes without accounting for changes over time; the genotype+time model additionally considered non-linear time trends;

and the genotype\*time model also considered interactions leading to changes in spline slope between genotypes. We report p-values derived from all 3 models in [S5 Table](#); plots show the p-value for the most complex statistical model (i, ii, or iii) meeting our significance threshold of  $\alpha = 5 \times 10^{-5}$ .

We also applied longitudinal mixed effects models and the same statistical threshold ( $p < 5 \times 10^{-5}$ ) to identify those genetic manipulations (*elav*>*RNAi* / + or *allele* / +) causing a locomotor phenotype that was significantly different from *elav*-*GAL4* / + control flies, independent of  $\alpha$ Syn. Genetic manipulations that were not significantly different from controls ( $p > 5 \times 10^{-5}$ ) were classified as “no/mild” toxicity. For all others showing significant differences ( $p < 5 \times 10^{-5}$ ), we further classified the strength of phenotype by comparing the *elav*>*RNAi* (or *allele* / +) locomotor phenotype to that caused by *elav*> $\alpha$ Syn. Those genetic manipulations causing locomotor phenotypes that were less extreme than *elav*> $\alpha$ Syn were considered “moderate” toxicity. If the locomotor phenotype curve crossed the *elav*> $\alpha$ Syn curve to produce a more extreme climbing impairment, we considered this indicative of “severe” toxicity.

For the retinal histology assay, comparisons of vacuolar degenerative change were made using a 2-tailed student's unpaired t-test followed by Dunnett's post-hoc test for multiple comparisons, implemented in GraphPad Prism. For the  $\alpha$ Syn ELISA, concentration of  $\alpha$ Syn was estimated from fluorescence intensity using an interpolated standard curve. Comparisons of  $\alpha$ Syn concentrations were made using ANOVA with Dunnett's multiple comparisons post-hoc test, also in GraphPad Prism. Except as noted above, differential expression analysis of *Drosophila* proteomics data was performed using default DESeq2 parameters, which implements a Wald test, and differentially expressed proteins were filtered using a significance threshold of Benjamini-Hochberg adjusted p-value  $< 0.05$ . For visualization, t-tests were used to compare the normalized abundance levels between control and  $\alpha$ Syn flies for each selected gene. For replication of *Drosophila* proteomics in the longitudinal dataset, we used linear regression with protein expression as an outcome, genotype as a predictor, and including age as a covariate: expression  $\sim$  genotype + age. Significance was computed using the Likelihood-ratio test, comparing to a base model: expression  $\sim$  age. Significance was set for a Benjamini-Hochberg adjusted p-value  $< 0.05$ . For the analysis of MANBA from human PPMI proteomics, the Wilcoxon rank sum test was implemented via the *geom\_signif* function in the R package, *ggsignif*.

## Supporting information

**S1 Fig. Locomotor screen validation data.** Data is shown for all modifiers of the  $\alpha$ -synuclein ( $\alpha$ Syn) locomotor phenotype. Pan-neuronal expression of human  $\alpha$ -synuclein (Red: *elav* >  $\alpha$ Syn) induces progressive locomotor impairment versus control flies (Green: *elav*-*GAL4* / +). Homologs were manipulated using RNA-interference (RNAi) or using loss-of-function alleles (*allele*). Each modifier gene was tested in heterozygosity, both in the presence (Purple: *elav*> $\alpha$ Syn + modifier) or absence (Blue: *elav*>RNAi or *elav*-*GAL4* + *allele*) of  $\alpha$ Syn. Statistical comparisons based on one-way ANOVA considering three nested models (genotype, genotype + time, and genotype\*time) and reporting results for the most complex model meeting significance. See also [S5 Table](#) for detailed statistical output. Significance testing examined whether modifier genes enhance the  $\alpha$ Syn-induced locomotor impairment [p(+ syn)] and whether gene manipulations cause locomotor phenotypes independent of  $\alpha$ Syn [p(- syn)]. The 2 comparisons (*i.* and *ii.*) are indicated on the second plot shown (A, *Npc1a*<sup>1</sup>). We classified modifier strains based on the severity of phenotype produced independent of  $\alpha$ Syn. Genetic manipulations that were not significantly different from controls ( $p > 5 \times 10^{-5}$ ) were classified as “no/mild” toxicity (A). For all others showing significant differences ( $p < 5 \times 10^{-5}$ ), we further

classified the strength of phenotype by comparing the *elav>RNAi* (or *allele / +*) locomotor phenotype to that caused by *elav> $\alpha$ Syn*. Those genetic manipulations causing locomotor phenotypes that were less extreme than *elav> $\alpha$ Syn* were considered “moderate” (B). If the locomotor phenotype curve crossed the *elav> $\alpha$ Syn* curve to produce a more extreme climbing impairment, we considered this indicative of “severe” toxicity (C).

(PDF)

**S2 Fig. Validation of RNA-interference (RNAi) strains and other alleles.** Reverse transcription polymerase chain reaction (RT-PCR) was performed to confirm RNAi knockdown of selected genes. Total mRNA was prepared from the heads of 10-day old female flies. RNAi transgenes or alleles were tested in heterozygosity (e.g., *Elav-GAL4 / +*; *UAS-RNAi* or *allele / +*). The following RNAi strains were tested: *Gba1b* (KD1: *v21336*, KD2: *v101212*);  *$\beta$ -Man* (KD1: *12582R-2*, KD2: *v110464*); *Csp* (KD1: *6395R-2*, KD2: *v103201*); *Dsb* (KD1: *v4100*, KD2: *v100219*); *Lip4* (KD1: *v31021*, KD2: *v106614*); *Npc1a* (*v105405*). Quantification based on analysis of at least  $n = 4$  animals per genotype. Statistical comparisons were made using unpaired t-tests, followed by Dunnett’s post-hoc test. Error bars represent the standard error of the mean. \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ ; \*\*\*\*,  $p < 0.0001$ ; ns, non-significant

(TIF)

**S3 Fig. Overexpression of Lip4 and Npc1a.** Pan-neuronal overexpression of *Lip4* (A) or *Npc1a* (B) using the *elav-GAL4* driver mildly enhances the  $\alpha$ -synuclein locomotor phenotype. *Npc1a* overexpression caused locomotor impairment independent of  $\alpha$ -synuclein. Climbing speed was assessed longitudinally, including at least 11 aged time points over 30 days ( $n > 6$  replicates of 15 animals each). As in S1 Fig, statistical comparisons were based on one-way ANOVA, examining whether genetic manipulations modify locomotor behavior either in the presence [p(+ syn)] or absence [p(- syn)] of  $\alpha$ -synuclein.

(TIF)

**S4 Fig. Analysis of cholesterol levels following manipulation of storage disorder genes.**

Cholesterol and cholesterol esters are modestly increased following *Npc1a* (left) or *Lip4* (right) loss-of-function. Homogenates were prepared from heads of 10-day old female flies. All RNAi transgenes or alleles were tested in heterozygosity and in the presence of the *elav-GAL4* pan-neuronal driver. The following RNAi strains were tested: *Npc1a* (*v105405*), *Lip4* (KD1: *v31021*; KD2: *v106614*). Quantification based on analysis of at least  $n = 5$  replicate samples per genotype. Statistical comparisons were made using unpaired t-tests, followed by Dunnett’s post-hoc test. Error bars represent the standard error of the mean. \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*\*,  $p < 0.0001$

(TIF)

**S5 Fig. Analysis of lysosomal function following manipulation of lysosomal storage disorder genes.**

Markers of lysosomal function, including autophagic flux (A, p62) or Cathepsin L (CTSL) proteolysis (B, C), was assayed following *Npc1a* or *Lip4* loss-of-function. Gene knockdown using RNA interference (RNAi) transgenes or loss-of-function alleles were tested in heterozygosity with *elav-GAL4* and in either the presence or absence of  $\alpha$ -synuclein. Western blots were performed on homogenates prepared from heads of 10-day old female flies and probed for p62 (A) or CTSL (B, C). The native CTSL proform, proCTSL (B), is cleaved in the acidic environment of the lysosome to generate the mature form, mCTSL (C). *Npc1a*<sup>1</sup> caused an increase in both proCTSL and mCTSL, but this result was not seen consistently for other alleles or RNAi. The following RNAi strains were tested: *Npc1a* (*v105405*), *Lip4* (KD1: *v31021*; KD2: *v106614*). We used the *v2691* strain as a non-targeting, scramble RNAi. Quantification based on analysis of at least  $n = 4$  replicate samples per genotype. Statistical comparisons were



made using unpaired t-tests, followed by Dunnett's post-hoc test. Error bars represent the standard error of the mean. \*\*\*,  $p < 0.001$ ; \*\*\*\*,  $p < 0.0001$  See [S6 Fig](#) for original western blot data.

(TIF)

**S6 Fig. Markers of lysosomal function following manipulation of lysosomal storage disorder genes.** Original western blot data is shown for investigations of markers of lysosomal function, including autophagic flux (p62) or Cathepsin L (CTSL) proteolysis, following *Npc1a* or *Lip4* loss-of function. The following RNAi strains were tested: *Npc1a* (*v105405*), *Lip4* (KD1: *v31021*; KD2: *v106614*). We used the *v2691* strain as a non-targeting, scramble RNAi. See [S5 Fig](#) for quantitation and statistical analysis of these data. For quantitation, all intensity data was normalized to mean intensity of *elav>syn* bands on each blot, permitting an integrated analysis. Poorly-transferred p62 bands were excluded from analysis, including all of the *elav>+* control lanes on the *Npc1a*<sup>57</sup> blot (middle row, right) and one of the *elav>Lip4*<sup>KD2/+</sup> control lanes (top row, right).

(TIF)

**S7 Fig. Studies of  $\alpha$ -synuclein protein expression.** Enzyme linked immunosorbent assays (ELISA) were performed for quantification of total  $\alpha$ -synuclein levels from 10-day-old fly head homogenates.  $\alpha$ -synuclein was expressed pan-neuronally using the *elav-GAL4* driver (*elav> $\alpha$ syn*). LSD gene modifiers were manipulated using RNA interference knockdown (RNAi) or loss-of-function alleles; all such manipulations were tested in heterozygosity. (A)  $\alpha$ -synuclein protein is sensitively and specifically detected by the ELISA in *elav> $\alpha$ syn* flies but not wildtype controls.  $\alpha$ -synuclein protein levels are unchanged following co-expression of a non-targeting *UAS-RNAi-scramble* control construct. (B) Manipulations of either *Npc1a*, *Lip4*, or *Csp* do not cause any consistent changes in  $\alpha$ -synuclein protein levels. The following RNAi strains were tested: *Npc1a* (*v105405*), *Lip4* (KD1: *v31021*; KD2: *v106614*), *Csp* (KD1: *6395R-2*, KD2: *v103201*). (C) For all other LSD gene modifiers, the RNAi transgene generating the strongest locomotor phenotype was selected for ELISAs: *Ect3* (*3132R-2*); *Idua* (*v13244*); *Dsb* (*v4100*);  $\beta$ -*Man* (*v15028*); *Snmp1* (*v42496*); *Gbalb* (*v101212*); *CG15533* (*v102842*); *Ids* (*v105970*); *LManII* (*v108218*); *CG10104* (*v108431*); *Gntap* (*v109400*); *MFS3* (*v330237*). Only knockdown of *LManII* caused a significant increase in  $\alpha$ -synuclein protein levels. Reduction of *MFS3* decreased  $\alpha$ -synuclein protein levels. All other manipulations did not significantly impact  $\alpha$ -synuclein protein levels. Quantification based on analysis of at least  $n = 5$  replicate samples per genotype. Statistical comparisons were made using unpaired t-tests, followed by Dunnett's post-hoc test. Error bars represent the standard error of the mean. \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*\*,  $p < 0.0001$

(TIF)

**S8 Fig. Additional studies of  $\alpha$ -synuclein-induced retinal degeneration.** Representative images of retinal histology sections (A) and quantification (B) of additional *Npc1a* alleles and *Lip4* RNAi (*v106614*), showing consistent enhancement of  $\alpha$ -synuclein-mediated neurodegeneration. Quantification based on extent of vacuolar changes (vacuole area / total area) from at least  $n = 3$  animals per genotype. Statistical comparisons were made using unpaired t-tests, followed by Dunnett's post-hoc test. Error bars represent the standard error of the mean. \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ ; ns, non-significant; Scale bar = 20 $\mu$ m.

(TIF)

**S9 Fig. Replication of lysosomal storage disorder protein differential expression.** (A, B) Adult fly head homogenates were prepared from *elav> $\alpha$ syn* or controls (*elav-GAL4 / +*), and Tandem Mass Tag proteomics were performed. (A) Cross-sectional comparisons of mean abundance from 10-day-old adults were analyzed using t-tests, considering  $n = 5$  replicate

samples for each genotype. Error bars represent the standard error of the mean. \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ . (B) Complementary longitudinal analysis, including 6 aging timepoints between 2 and 21 days. Regression models considered protein expression as an outcome, genotype as a predictor, and included age as a covariate:  $\text{expression} \sim \text{genotype} + \text{age}$ . Significance was computed using the Likelihood-ratio test, comparing to the base model:  $\text{expression} \sim \text{age}$ . Benjamini-Hochberg adjusted p-value is shown.  $\log_2\text{FC}$ , log base2 (fold-change). (C) MANBA protein levels were examined from human cerebrospinal fluid from the Parkinson's Progression Markers Initiative (PPMI), including 365 PD cases, 177 controls, and 111 prodromal PD cases, in which early disease biomarkers are present, but clinical manifestations are lacking for the diagnosis. MANBA was significantly elevated in prodromal PD and reduced in clinically manifest PD.

(TIF)

**S1 Table. Common variants associated with Parkinson's disease (PD) risk are enriched in lysosomal storage disorder (LSD) genes.** The multi-marker analysis of genomic annotation (MAGMA) tool [17] was used to test for enrichment among LSD gene sets (top) or 51 separate genes (bottom). As a sensitivity analysis, the LSD gene set tests were repeated following exclusion of either *GBA* or the top 3 genes (*GBA*, *SCARB2*, *IDUA*).

(XLSX)

**S2 Table. Conservation of Lysosomal Storage Disorder Genes in Drosophila.** Human and fly gene homologs are shown, along with level of conservation based on the Drosophila Integrated Ortholog Prediction Tool [66]. 86 fly gene homologs were tested in this study. For 6 genes, genetic reagents were not available for testing: *Fuca*, *Hexo2*, *CG42638*, *Ppt1*, *CG42638* and *CG40006*.

(XLSX)

**S3 Table. Genetic reagents for manipulation of fly homologs of human lysosomal storage disorder genes.** 259 genetic strains targeting 86 fly genes were tested, including RNA-interference (RNAi) and classical loss-of-function alleles. Detailed genotype information, the source of each line, and FlyBase ID are noted. Note: some of the RNAi lines tested in this study have been discarded by stock centers and may no longer be available. NA, not applicable.

(XLSX)

**S4 Table. Fly homologs of proteins encoded by human lysosomal storage disorder (LSD) genes are dysregulated in  $\alpha$ -synuclein ( $\alpha$ Syn) transgenic flies.** Results from differential expression analysis are shown, based on mass spectrometry proteomics from  $\alpha$ Syn vs. control flies. 15 out of 22 differentially-expressed proteins were up-regulated in  $\alpha$ Syn flies.

(XLSX)

**S5 Table. Detailed statistical output from locomotor testing.**

(XLSX)

**S6 Table. Drosophila Mass-spectrometry Proteomics Discovery Study Metadata.** Sample identifiers are noted for control (Ctrl: *elav-GAL4* / +) and  $\alpha$ -synuclein transgenic (Exp) flies. 8 replicates for each genotype were included in this mass-spectrometry proteomics study with tandem mass tags. For full dataset see [S1 Dataset](#).

(XLSX)

**S7 Table. Drosophila Mass-spectrometry Proteomics Replication Study Metadata.** Sample identifiers and ages (days) are noted for control (*elav-GAL4* / +) and  $\alpha$ -synuclein transgenic flies. 5 replicates for each genotype were included in this longitudinal study. For full dataset



see [S2 Dataset](#).

(XLSX)

**S1 Dataset. *Drosophila* Proteomics Discovery Study.**

(TXT)

**S2 Dataset. *Drosophila* Proteomics Replication Study.**

(CSV)

**S3 Dataset. Primary data for graphical and statistical analyses.**

(XLSX)

## Acknowledgments

We thank our colleagues, Drs. Chun Han, Michael Hoch, and Linda Partridge for generously providing *Drosophila* strains. We also thank the Bloomington *Drosophila* stock center, the Vienna *Drosophila* RNAi Center, the TRiP at Harvard Medical School, the National Institute of Genetics, Japan, and FlyBase. We are grateful to Dr. Laurie Robak for helpful discussions and feedback on the manuscript.

## Author Contributions

**Conceptualization:** Meigen Yu, Duc Duong, Nicholas T. Seyfried, Ismael Al-Ramahi, Juan Botas, Joshua M. Shulman.

**Data curation:** Duc Duong.

**Formal analysis:** Meigen Yu, Ruth B. De-Paula, Carl Grant Mangleburg, Timothy Wu, Bridget Phillips, Genevera I. Allen.

**Funding acquisition:** Nicholas T. Seyfried, Juan Botas, Joshua M. Shulman.

**Investigation:** Meigen Yu, Hui Ye, Ruth B. De-Paula, Tom V. Lee, Yarong Li, Duc Duong, Bridget Phillips, Carlos Cruchaga, Juan Botas, Joshua M. Shulman.

**Methodology:** Genevera I. Allen, Ismael Al-Ramahi, Juan Botas.

**Resources:** Nicholas T. Seyfried, Juan Botas, Joshua M. Shulman.

**Software:** Carl Grant Mangleburg, Timothy Wu, Genevera I. Allen.

**Supervision:** Carlos Cruchaga, Nicholas T. Seyfried, Ismael Al-Ramahi, Juan Botas, Joshua M. Shulman.

**Validation:** Tom V. Lee.

**Visualization:** Carl Grant Mangleburg, Timothy Wu, Bridget Phillips.

**Writing – original draft:** Meigen Yu, Joshua M. Shulman.

**Writing – review & editing:** Meigen Yu, Hui Ye, Ruth B. De-Paula, Carl Grant Mangleburg, Tom V. Lee, Yarong Li, Duc Duong, Bridget Phillips, Carlos Cruchaga, Genevera I. Allen, Nicholas T. Seyfried, Ismael Al-Ramahi, Juan Botas, Joshua M. Shulman.

## References

1. Ye H, Robak LA, Yu M, Cykowski M, Shulman JM. Genetics and Pathogenesis of Parkinson's Syndrome. *Annu Rev Pathol*. 2022 Jan 24; 18(1). <https://doi.org/10.1146/annurev-pathmechdis-031521-034145> PMID: 36100231

2. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease. *New England Journal of Medicine*. 2009 Oct 22; 361(17): 1651–61. <https://doi.org/10.1056/NEJMoa0901281> PMID: 19846850
3. Pastores GM, Hughes DA. Gaucher Disease. 2018 Jun 21; Available from: <http://europepmc.org/books/NBK1269>
4. Hein LK, Meikle PJ, Hopwood JJ, Fuller M. Secondary sphingolipid accumulation in a macrophage model of Gaucher disease. *Mol Genet Metab*. 2007 Dec 1; 92(4): 336–45. <https://doi.org/10.1016/j.ymgme.2007.08.001> PMID: 17881272
5. Surface M, Balwani M, Waters C, Haimovich A, Gan-Or Z, Marder KS, et al. Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease. *Mov Disord*. 2022 Feb 1; 37(2): 416–21. <https://doi.org/10.1002/mds.28846> PMID: 34741486
6. Platt FM, d'Azzo A, Davidson BL, Neufeld EF, Tiffit CJ. Lysosomal storage diseases. *Nature Reviews Disease Primers* 2018 4:1. 2018 Oct 1; 4(1): 1–25.
7. Gan-Or Z, Ozelius LJ, Bar-Shira A, Saunders-Pullman R, Mirelman A, Kornreich R, et al. The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease. *Neurology*. 2013 Apr 23; 80(17): 1606–10. <https://doi.org/10.1212/WNL.0b013e31828f180e> PMID: 23535491
8. Robak LA, Jansen IE, van Rooij J, Uitterlinden AG, Kraaij R, Jankovic J, et al. Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease. *Brain*. 2017 Dec 1; 140(12): 3191–203. <https://doi.org/10.1093/brain/awx285> PMID: 29140481
9. Straniero L, Rimoldi V, Monfrini E, Bonvegna S, Melistaccio G, Lake J, et al. Role of Lysosomal Gene Variants in Modulating GBA-Associated Parkinson's Disease Risk. *Movement Disorders*. 2022 Jun 1; 37(6): 1202–10. <https://doi.org/10.1002/mds.28987> PMID: 35262230
10. Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet Neurol*. 2019 Dec 1; 18(12): 1091–102. [https://doi.org/10.1016/S1474-4422\(19\)30320-5](https://doi.org/10.1016/S1474-4422(19)30320-5) PMID: 31701892
11. Mazzulli JR, Zunke F, Isacson O, Studer L, Krainc D.  $\alpha$ -Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. *Proc Natl Acad Sci USA*. 2016 Feb 16; 113(7): 1931–6.
12. Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, et al. Gaucher disease glucocerebrosidase and  $\alpha$ -synuclein form a bidirectional pathogenic loop in synucleinopathies. *Cell*. 2011 Jul 8; 146(1): 37–52.
13. Murphy KE, Gysbers AM, Abbott SK, Tayebi N, Kim WS, Sidransky E, et al. Reduced glucocerebrosidase is associated with increased  $\alpha$ -synuclein in sporadic Parkinson's disease. *Brain*. 2014 Mar 1; 137(3): 834–48.
14. Fernandes HJR, Hartfield EM, Christian HC, Emmanouilidou E, Zheng Y, Booth H, et al. ER Stress and Autophagic Perturbations Lead to Elevated Extracellular  $\alpha$ -Synuclein in GBA-N370S Parkinson's iPSC-Derived Dopamine Neurons. *Stem Cell Reports*. 2016 Mar 8; 6(3): 342–56.
15. Zunke F, Moise AC, Belur NR, Gelyana E, Stojkowska I, Dzaferbegovic H, et al. Reversible Conformational Conversion of  $\alpha$ -Synuclein into Toxic Assemblies by Glucosylceramide. *Neuron*. 2018 Jan 3; 97(1): 92.
16. Taguchi Y v., Liu J, Ruan J, Pacheco J, Zhang X, Abbasi J, et al. Glucosylsphingosine Promotes  $\alpha$ -Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease. *The Journal of Neuroscience*. 2017 Oct 4; 37(40): 9617.
17. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. *PLoS Comput Biol*. 2015 Apr 1; 11(4). <https://doi.org/10.1371/journal.pcbi.1004219> PMID: 25885710
18. Feany MB, Bender WW. A *Drosophila* model of Parkinson's disease. *Nature*. 2000 Mar 23; 404(6776): 394–8. <https://doi.org/10.1038/35006074> PMID: 10746727
19. Chouhan AK, Guo C, Hsieh YC, Ye H, Senturk M, Zuo Z, et al. Uncoupling neuronal death and dysfunction in *Drosophila* models of neurodegenerative disease. *Acta Neuropathol Commun*. 2016; 4(1): 62. <https://doi.org/10.1186/s40478-016-0333-4> PMID: 27338814
20. Onur TS, Laitman A, Zhao H, Keyho R, Kim H, Wang J, et al. Downregulation of glial genes involved in synaptic function mitigates huntington's disease pathogenesis. *Elife*. 2021 May 1; 10. <https://doi.org/10.7554/eLife.64564> PMID: 33871358
21. Rousseaux MWC, Vázquez-Vélez GE, Al-Ramahi I, Jeong HH, Bajić A, Revelli JP, et al. A Druggable Genome Screen Identifies Modifiers of  $\alpha$ -Synuclein Levels via a Tiered Cross-Species Validation Approach. *Journal of Neuroscience*. 2018 Oct 24; 38(43): 9286–301.

22. Dietzl G, Chen D, Schnorrer F, Su KC, Barinova Y, Fellner M, et al. A genome-wide transgenic RNAi library for conditional gene inactivation in *Drosophila*. *Nature* 2007 448:7150. 2007 Jul 12; 448(7150): 151–6. <https://doi.org/10.1038/nature05954> PMID: 17625558
23. Perkins LA, Holderbaum L, Tao R, Hu Y, Sopko R, McCall K, et al. The transgenic RNAi project at Harvard medical school: Resources and validation. *Genetics*. 2015 Nov 1; 201(3): 843–52. <https://doi.org/10.1534/genetics.115.180208> PMID: 26320097
24. Phillips SE, Woodruff EA, Liang P, Patten M, Broadie K, Broadie K. Neuronal loss of *Drosophila* NPC1a causes cholesterol aggregation and age-progressive neurodegeneration. *J Neurosci*. 2008 Jun 25; 28(26):6569–82. <https://doi.org/10.1523/JNEUROSCI.5529-07.2008> PMID: 18579730
25. Jansen IE, Ye H, Heetveld S, Lechler MC, Michels H, Seinstra RI, et al. Discovery and functional prioritization of Parkinson's disease candidate genes from large-scale whole exome sequencing. *Genome Biol*. 2017 Dec 30; 18(1):22. <https://doi.org/10.1186/s13059-017-1147-9> PMID: 28137300
26. Alcalay RN, Mallett V, Vanderperre B, Tavassoly O, Dauvilliers Y, Wu RYJ, et al. SMPD1 mutations, activity, and  $\alpha$ -synuclein accumulation in Parkinson's disease. *Movement Disorders*. 2019 Apr 1; 34(4): 526–35.
27. McGlinchey RP, Lee JC. Cysteine cathepsins are essential in lysosomal degradation of  $\alpha$ -synuclein. *Proc Natl Acad Sci U S A*. 2015 Jul 28; 112(30): 9322–7.
28. Sevlever D, Jiang P, Yen SHC. Cathepsin D is the main lysosomal enzyme involved in the degradation of  $\alpha$ -synuclein and generation of its carboxy-terminally truncated species. *Biochemistry*. 2008 Sep 9; 47(36): 9678–87.
29. Mak SK, McCormack AL, Manning-Bog AB, Cuervo AM, di Monte DA. Lysosomal degradation of alpha-synuclein in vivo. *J Biol Chem*. 2010 Apr 30; 285(18): 13621–9. <https://doi.org/10.1074/jbc.M109.074617> PMID: 20200163
30. Lee HJ, Khoshaghideh F, Patel S, Lee SJ. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. *J Neurosci*. 2004 Feb 25; 24(8): 1888–96. <https://doi.org/10.1523/JNEUROSCI.3809-03.2004> PMID: 14985429
31. Rothaug M, Zunke F, Mazzulli JR, Schweizer M, Altmepfen H, Lüllmann-Rauche R, et al. LIMP-2 expression is critical for  $\beta$ -glucocerebrosidase activity and  $\alpha$ -synuclein clearance. *Proc Natl Acad Sci USA*. 2014 Oct 28; 111(43): 15573–8.
32. Mehra S, Ghosh D, Kumar R, Mondal M, Gadhe LG, Das S, et al. Glycosaminoglycans have variable effects on  $\alpha$ -synuclein aggregation and differentially affect the activities of the resulting amyloid fibrils. *Journal of Biological Chemistry*. 2018 Aug 24; 293(34): 12975–91.
33. Holmes BB, DeVos SL, Kfoury N, Li M, Jacks R, Yanamandra K, et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. *Proc Natl Acad Sci USA*. 2013 Aug 13; 110(33). <https://doi.org/10.1073/pnas.1301440110> PMID: 23898162
34. Bosco DA, Fowler DM, Zhang Q, Nieva J, Powers ET, Wentworth P, et al. Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate  $\alpha$ -synuclein fibrilization. *Nature Chemical Biology* 2006 2:5. 2006 Mar 26; 2(5): 249–53.
35. Fortin DL, Troyer MD, Nakamura K, Kubo SI, Anthony MD, Edwards RH. Lipid Rafts Mediate the Synaptic Localization of  $\alpha$ -Synuclein. *Journal of Neuroscience*. 2004 Jul 28; 24(30): 6715–23.
36. Hu G, Antikainen R, Jousilahti P, Kivipelto M, Tuomilehto J. Total cholesterol and the risk of Parkinson disease. *Neurology*. 2008 May 20; 70(21): 1972–9. <https://doi.org/10.1212/01.wnl.0000312511.62699.a8> PMID: 18401018
37. Huang X, Auinger P, Eberly S, Oakes D, Schwarzschild M, Ascherio A, et al. Serum Cholesterol and the Progression of Parkinson's Disease: Results from DATATOP. *PLoS One*. 2011; 6(8):e22854. <https://doi.org/10.1371/journal.pone.0022854> PMID: 21853051
38. de Lau LML, Koudstaal PJ, Hofman A, Breteler MMB. Serum Cholesterol Levels and the Risk of Parkinson's Disease. *Am J Epidemiol*. 2006 Nov 15; 164(10): 998–1002. <https://doi.org/10.1093/aje/kwj283> PMID: 16905642
39. Rozani V, Gurevich T, Giladi N, El-Ad B, Tsamir J, Hemo B, et al. Higher serum cholesterol and decreased Parkinson's disease risk: A statin-free cohort study. *Movement Disorders*. 2018 Aug 1; 33(8): 1298–305. <https://doi.org/10.1002/mds.27413> PMID: 30145829
40. Gudala K, Bansal D, Muthyala H. Role of Serum Cholesterol in Parkinson's Disease: A Meta-Analysis of Evidence. *J Parkinsons Dis*. 2013 Jan 1; 3(3): 363–70. <https://doi.org/10.3233/JPD-130196> PMID: 23948990
41. Ouled Amar Bencheikh B, Senkevich K, Rudakou U, Yu E, Mufti K, Ruskey JA, et al. Variants in the Niemann–Pick type C gene NPC1 are not associated with Parkinson's disease. *Neurobiol Aging*. 2020 Sep 1; 93:143.e1–143.e4. <https://doi.org/10.1016/j.neurobiolaging.2020.03.021> PMID: 32371106

42. Zech M, Nübling G, Castrop F, Jochim A, Schulte EC, Mollenhauer B, et al. Niemann-Pick C Disease Gene Mutations and Age-Related Neurodegenerative Disorders. *PLoS One*. 2013 Dec 30; 8(12): e82879. <https://doi.org/10.1371/journal.pone.0082879> PMID: 24386122
43. Porter FD, Scherrer DE, Lanier MH, Langmade SJ, Molugu V, Gale SE, et al. Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. *Sci Transl Med*. 2010 Nov 3; 2(56). <https://doi.org/10.1126/scitranslmed.3001417> PMID: 21048217
44. Kruth HS, Comlyg ME, Butlerl JD, Vanierl MT, Finks JK, Wenger DA, et al. Type C Niemann-Pick disease. Abnormal metabolism of low density lipoprotein in homozygous and heterozygous fibroblasts. *Journal of Biological Chemistry*. 1986; 261(35): 16769–74. PMID: 3782141
45. Josephs KA, Matsumoto JY, Lindor NM. Heterozygous Niemann-Pick disease type C presenting with tremor. *Neurology*. 2004 Dec 14; 63(11): 2189–90. <https://doi.org/10.1212/01.wnl.0000145710.25588.2f> PMID: 15596783
46. Klunemann HH, Nutt JG, Davis MY, Bird TD. Parkinsonism syndrome in heterozygotes for Niemann-Pick C1. *J Neurol Sci*. 2013 Dec 15; 335(1–2): 219–20. <https://doi.org/10.1016/j.jns.2013.08.033> PMID: 24035292
47. Brunngraber EG, Berra B, Zambotti V. Altered levels of tissue glycoproteins, gangliosides, glycosaminoglycans and lipids in niemann-pick's disease. *Clinica Chimica Acta*. 1973 Oct 12; 48(2): 173–81. [https://doi.org/10.1016/0009-8981\(73\)90363-x](https://doi.org/10.1016/0009-8981(73)90363-x) PMID: 4271344
48. Malini E, Grossi S, Deganuto M, Rosano C, Parini R, Dominisni S, et al. Functional analysis of 11 novel GBA alleles. *European Journal of Human Genetics* 2014 22:4. 2013 Sep 11; 22(4): 511–6. <https://doi.org/10.1038/ejhg.2013.182> PMID: 24022302
49. Pentchev PG, Neumeyer B, Svennerholm L, Groth CG, Brady RO. Immunological and catalytic quantitation of splenic glucocerebrosidase from the three clinical forms of Gaucher disease. *Am J Hum Genet*. 1983; 35(4): 621. PMID: 6881138
50. Khair SBA, Dhanushkodi NR, Ardah MT, Chen W, Yang Y, Haque ME. Silencing of Glucocerebrosidase Gene in *Drosophila* Enhances the Aggregation of Parkinson's Disease Associated  $\alpha$ -Synuclein Mutant A53T and Affects Locomotor Activity. *Front Neurosci*. 2018 Feb 16; 12.
51. Davis MY, Trinh K, Thomas RE, Yu S, Germanos AA, Whitley BN, et al. Glucocerebrosidase Deficiency in *Drosophila* Results in  $\alpha$ -Synuclein-Independent Protein Aggregation and Neurodegeneration. *PLoS Genet*. 2016 Mar; 12(3):e1005944.
52. Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, et al. Ageing as a risk factor for neurodegenerative disease. *Nat Rev Neurol*. 2019 Oct 1; 15(10):565–81. <https://doi.org/10.1038/s41582-019-0244-7> PMID: 31501588
53. Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, Gennarino VA, et al. A gene network regulating lysosomal biogenesis and function. *Science*. 2009 Jul 24; 325(5939): 473–7. <https://doi.org/10.1126/science.1174447> PMID: 19556463
54. Bouché V, Espinosa AP, Leone L, Sardiello M, Ballabio A, Botas J. *Drosophila* Mitf regulates the V-ATPase and the lysosomal-autophagic pathway. *Autophagy*. 2016; 12(3): 484–98. <https://doi.org/10.1080/15548627.2015.1134081> PMID: 26761346
55. Davie K, Janssens J, Koldere D, de Waegeneer M, Pech U, Kreft L, et al. A Single-Cell Transcriptome Atlas of the Aging *Drosophila* Brain. *Cell*. 2018 Aug 9; 174(4):982–998.e20 <https://doi.org/10.1016/j.cell.2018.05.057> PMID: 29909982
56. Wang L, Lin G, Zuo Z, Li Y, Byeon SK, Pandey A, et al. Neuronal activity induces glucosylceramide that is secreted via exosomes for lysosomal degradation in glia. *Sci Adv*. 2022 Jul 15; 8(28): 3326. <https://doi.org/10.1126/sciadv.abn3326> PMID: 35857503
57. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics*. 2010 Jan 28; 26(6): 841–2. <https://doi.org/10.1093/bioinformatics/btq033> PMID: 20110278
58. Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. *Development*. 1993 Jun 1; 118(2): 401–15. <https://doi.org/10.1242/dev.118.2.401> PMID: 8223268
59. Lin DM, Goodman CS. Ectopic and increased expression of fasciclin II alters motoneuron growth cone guidance. *Neuron*. 1994 Sep 1; 13(3): 507–23. [https://doi.org/10.1016/0896-6273\(94\)90022-1](https://doi.org/10.1016/0896-6273(94)90022-1) PMID: 7917288
60. Xiong B, Bayat V, Jaiswal M, Zhang K, Sandoval H, Chang WL, et al. Crag Is a GEF for Rab11 Required for Rhodopsin Trafficking and Maintenance of Adult Photoreceptor Cells. *PLoS Biol*. 2012 Dec; 10(12):e1001438. <https://doi.org/10.1371/journal.pbio.1001438> PMID: 23226104
61. Han C, Song Y, Xiao H, Wang D, Franc NC, Yeh Jan L, et al. Epidermal Cells Are the Primary Phagocytes in the Fragmentation and Clearance of Degenerating Dendrites in *Drosophila*. *Neuron*. 2014 Feb 5; 81(3): 544–60. <https://doi.org/10.1016/j.neuron.2013.11.021> PMID: 24412417

62. Wingen A, Carrera P, Ekaterini Psathaki O, Voelzmann A, Paululat A, Hoch M. Debris buster is a *Drosophila* scavenger receptor essential for airway physiology. *Dev Biol*. 2017 Oct 1; 430(1): 52–68. <https://doi.org/10.1016/j.ydbio.2017.08.018> PMID: 28821389
63. Liu L, Zhang K, Sandoval H, Yamamoto S, Jaiswal M, Sanz E, et al. Glial lipid droplets and ROS induced by mitochondrial defects promote neurodegeneration. *Cell*. 2015 Jan 15; 160(1–2): 177–90. <https://doi.org/10.1016/j.cell.2014.12.019> PMID: 25594180
64. Huang X, Suyama K, Buchanan JA, Zhu AJ, Scott MP. A *Drosophila* model of the Niemann-Pick type C lysosome storage disease: *dnp1a* is required for molting and sterol homeostasis. *Development*. 2005 Nov; 132(22): 5115–24. <https://doi.org/10.1242/dev.02079> PMID: 16221727
65. Kinghorn KJ, Grönke S, Castillo-Quan JI, Woodling NS, Li L, Sirka E, et al. A *Drosophila* Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signaling and Is Functionally Rescued by Rapamycin. *J Neurosci*. 2016 Nov 16; 36(46): 11654–70. <https://doi.org/10.1523/JNEUROSCI.4527-15.2016> PMID: 27852774
66. Hu Y, Flockhart I, Vinayagam A, Bergwitz C, Berger B, Perrimon N, et al. An integrative approach to ortholog prediction for disease-focused and other functional studies. *BMC Bioinformatics*. 2011 Aug 31; 12. <https://doi.org/10.1186/1471-2105-12-357> PMID: 21880147
67. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. *Nat Methods*. 2012 Jul; 9(7): 671–5. <https://doi.org/10.1038/nmeth.2089> PMID: 22930834
68. Toni LS, Garcia AM, Jeffrey DA, Jiang X, Stauffer BL, Miyamoto SD, et al. Optimization of phenol-chloroform RNA extraction. *MethodsX*. 2018 Jan 1; 5: 599–608. <https://doi.org/10.1016/j.mex.2018.05.011> PMID: 29984193
69. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. *Nature Protocols* 2008 3:6. 2008 Jun 5; 3(6): 1101–8.
70. Rui YN, Xu Z, Patel B, Chen Z, Chen D, Tito A, et al. Huntingtin functions as a scaffold for selective macroautophagy. *Nat Cell Biol*. 2015 Mar 2; 17(3): 262–75. <https://doi.org/10.1038/ncb3101> PMID: 25686248
71. Johnson ECB, Carter EK, Dammer EB, Duong DM, Gerasimov ES, Liu Y, et al. Large-scale deep multi-layer analysis of Alzheimer’s disease brain reveals strong proteomic disease-related changes not observed at the RNA level. *Nat Neurosci*. 2022 Feb 1; 25(2): 213–25. <https://doi.org/10.1038/s41593-021-00999-y> PMID: 35115731
72. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol*. 2014 Dec 5; 15(12). <https://doi.org/10.1186/s13059-014-0550-8> PMID: 25516281
73. Mangleburg CG, Wu T, Yalamanchili HK, Guo C, Hsieh YC, Duong DM, et al. Integrated analysis of the aging brain transcriptome and proteome in tauopathy. *Mol Neurodegener*. 2020 Sep 29; 15(1). <https://doi.org/10.1186/s13024-020-00405-4> PMID: 32993812
74. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020.
75. Bates D, Mächler M, Bolker BM, Walker SC. Fitting Linear Mixed-Effects Models using lme4. *J Stat Softw*. 2014 Jun 23; 67(1).
76. Gu C. Smoothing Spline ANOVA Models. 2002; Available from: <http://link.springer.com/10.1007/978-1-4757-3683-0>